Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
AstraZeneca
National Institutes of Health Clinical Center (CC)
ViroMissile, Inc.
Seagen Inc.
MacroGenics
City of Hope Medical Center
Jiangsu Simcere Pharmaceutical Co., Ltd.
NeoTX Therapeutics Ltd.
West China Hospital
Coherus Oncology, Inc.
Pfizer
GONGCHU Biotechnology Co., Ltd
Exelixis
Jonsson Comprehensive Cancer Center
University of Virginia
Incyte Corporation
Incyte Corporation
HC Biopharma Inc.
Bristol-Myers Squibb
Aptamer Sciences, Inc.
Sichuan University
Sotio Biotech Inc.
Carisma Therapeutics Inc
Molecular Templates, Inc.
National Cancer Institute (NCI)
Xencor, Inc.
Second Affiliated Hospital of Guangzhou Medical University
BioEclipse Therapeutics
University of Florida
Bayer
Lebanese University
Fate Therapeutics
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Provectus Pharmaceuticals
AbbVie
Pfizer
AbbVie
Incyte Corporation
Eli Lilly and Company
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Sichuan Huiyang Life Science and Technology Corporation
Inovio Pharmaceuticals
National Cancer Institute (NCI)
Alliancells-PuRui Biocience Co., Ltd.